{"id":4915,"date":"2025-10-20T14:51:32","date_gmt":"2025-10-20T04:51:32","guid":{"rendered":"\/eu-uk\/?p=4915"},"modified":"2025-10-20T14:51:32","modified_gmt":"2025-10-20T04:51:32","slug":"orthocell-secures-global-distribution-rights-to-innovative-bone-regeneration-technology","status":"publish","type":"post","link":"\/eu-uk\/blog\/2025\/10\/20\/orthocell-secures-global-distribution-rights-to-innovative-bone-regeneration-technology\/","title":{"rendered":"Orthocell secures global distribution rights to innovative bone regeneration technology"},"content":{"rendered":"

Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical – from 1.7% to 12.0% for a total consideration of AU$1.0 million – securing exclusive first right of refusal over global distribution rights their groundbreaking bone substitute product, PearlBone\u2122.<\/span>\u00a0<\/span><\/p>\n

Developed using sustainably sourced pearl shells from the West Australian Kimberley coast, PearlBone is an innovative, next-generation biomaterial with promising applications in bone repair and regeneration in the orthopaedic, trauma and reconstructive surgery market.\u00a0<\/span>\u00a0<\/span><\/p>\n

Marine Biomedical is well advanced in its path to US regulatory approval of PearlBone, nearing completion of its pivotal study designed to support a U.S. FDA 510(k) marketing submission in 1Q CY26 to commercially distribute PearlBone into the US$1.6 billion bone substitute market.<\/span>\u00a0<\/span><\/p>\n

Orthocell Chair, John Van Der Wielen, said:\u00a0<\/span>\u00a0<\/span><\/p>\n

\u201cThis partnership delivers exactly what we look for \u2014 breakthrough science, a clear regulatory path, and immediate commercial synergy. With our strong surgeon relationships and global distribution channels, we are ideally positioned to bring this first-in-class product to market. Marine Biomedical has had significant grant support from the Western Australian Government and has been working for many years on the development of this product.\u201d\u00a0<\/em><\/p>\n

Read the ASX release<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical – from 1.7% to 12.0% for a total consideration of AU$1.0 million – securing exclusive first right of refusal over global distribution rights their groundbreaking bone substitute product, PearlBone\u2122.<\/p>\n","protected":false},"author":2,"featured_media":4916,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[2],"tags":[],"class_list":["post-4915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t